| Overview |
| bsm-70231M |
| Progesterone Receptor (Ser190) Antibody |
| WB, IHC |
| Specific for endogenous levels of the ~90 kDa PR-A isoform and the ~120 kDa PR-B isoform phosphorylated at Ser190. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser190 of human progesterone receptor, conjugated to keyhole limpet hemocyanin (KLH). |
| Ser190 |
| Monoclonal |
| 1154 |
| IgG1 |
| Lot Dependent |
| Purified by Protein G. |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 5241 |
| P06401 |
| NR3C3 antibody, Nuclear receptor subfamily 3 group C member 3 antibody, PGR antibody, PR antibody, PRA antibody, PRB antibody, PRGR_HUMAN antibody, Progesterone receptor antibody, Progestin receptor form A antibody, Progestin receptor form B antibody |
| There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005). The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000; Lin et al., 2003). Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser-190 and Ser-294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC |
|
Powered by Bioz